ONTRUZANT: payments to doctors
Payments that named ONTRUZANT as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $52K
- Providers
- 919
- Transactions
- 1,692
- Average per transaction
- $31
The per-transaction average — $31 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 919 providers the average total is $57, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Organon | $26,515 | 51.0% |
| Samsung Bioepis Co., Ltd. | $20,650 | 39.7% |
| Merck | $4,797 | 9.2% |